Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

15.53
-0.2300-1.46%
Volume:587.03K
Turnover:9.03M
Market Cap:1.32B
PE:-4.07
High:15.68
Open:15.68
Low:15.23
Close:15.76
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:0.75
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:3.09
PE(LYR):-4.40

Loading ...

Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential

TIPRANKS
·
May 11

MoonLake Q1 net loss widens 71.9% to $69.7 million

Reuters
·
May 11

MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)

TIPRANKS
·
May 11

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

MoonLake Immunotherapeutics Q1 Net Loss Widens

MT Newswires Live
·
May 11

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

TIPRANKS
·
May 11

MoonLake says aligned with FDA on submission plans for sonelokimab

TIPRANKS
·
May 11

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

TIPRANKS
·
May 11

MoonLake says FDA backs sonelokimab HS BLA plan, filing set for September 2026

Reuters
·
May 10

Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission

Reuters
·
May 10

MoonLake Immunotherapeutics - FDA Accepts Mira and Vela-Teen Trial Data for Sonelkimab Bla Submission

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome From Its Final Pre-Bla Meeting With the U.S. FDA and Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics - Bla Submission for Sonelkimab in Hs Planned for End of September 2026

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 10

Moonlake Immunotherapeutics announces annual shareholder meeting

Reuters
·
Apr 22

MoonLake CFO Matthias Bodenstedt disposes 2,426 shares for $47,444

Reuters
·
Apr 17

Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention

TIPRANKS
·
Apr 15

MoonLake CEO Jorge Santos da Silva sells USD 2.7 million shares

Reuters
·
Apr 15

MoonLake CFO Matthias Bodenstedt disposes of USD 1.7 million in common shares

Reuters
·
Apr 11